{"schema_version":"secwatch.filing_event.v1","accession":"0001062822-21-000055","form_type":"8-K","ticker":"LXRX","cik":"0001062822","company_name":"LEXICON PHARMACEUTICALS, INC.","filed_at":"2021-09-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:17.031080+00:00","generated_at":"2026-06-29T04:43:25.555716+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Lexicon appoints Jeffrey L. Wade as President, effective Oct 1, 2021; salary increased to $505k","bullets":["Jeffrey L. Wade, current EVP/CFO, promoted to President effective Oct 1, 2021; reports to CEO Lonnel Coats.","Base salary raised from $475,134 to $505,000; bonus target increased from 40% to 50% of base.","Wade has been with Lexicon since 1999, previously a partner at Andrews & Kurth L.L.P."],"urls":{"canonical":"https://secwatch.observer/filing/0001062822-21-000055","json":"https://secwatch.observer/filing/0001062822-21-000055.json","markdown":"https://secwatch.observer/filing/0001062822-21-000055.md","text":"https://secwatch.observer/filing/0001062822-21-000055.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1062822/000106282221000055/0001062822-21-000055-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1062822/000106282221000055/lxrx-20210903.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T04:43:25.555716+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"98c6ea7fc8","claim":"Jeffrey L. Wade was appointed as President at LEXICON PHARMACEUTICALS, INC..","evidence_excerpt":"On September 3, 2021, in preparation for the potential commercial launch of sotagliflozin, if approved, and management of future growth of our company, our board of directors appointed Jeffrey L. Wade as president, effective October 1, 2021, continuing to report to Lonnel Coats, who remains our chief executive officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282221000055/0001062822-21-000055-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}